# US 2017/0281557 A1 · Drug-containing particulate composition with cationic agent, associated medical devices, and methods for treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281557 A1
- Document ID: US20170281557A1
- Status: Published application
- Kind: A1
- Application number: 15/474,487
- Filed: 2017-03-30
- Published: 2017-10-05
- Earliest claimed: 2016-03-31
- Assignees: SurModics, Inc.
- Applicants: Surmodics, Inc.
- Inventors: Joram Slager
- Web page: https://patentgrep.com/patent/US20170281557A1

## CPC

- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K 9/5089: {Processes}
- A61K 31/365: Lactones
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61M 25/104: {used for angioplasty}
- A61M 2025/105: {having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The disclosure provides bioactive agent-containing particulates that include bioactive agent, biocompatible polymer, negatively charged groups, and a cationic agent. The particulates can be associated with a medical device, such as a balloon catheter, which can be used to move the particulates to a treatment site. Transfer of the particulates from the device to tissue is facilitated by the arrangement of the cationic and bioactive agent-containing particulates.

## Claims

### Claim 1

A bioactive agent delivery composition comprising
(a) a bioactive agent-containing particulate comprising:
a core particle comprising bioactive agent and a first biocompatible polymer; and a layer around the core particle comprising a second biocompatible polymer and that comprises negatively charged groups, wherein the second biocompatible polymer is more water soluble than the first biocompatible polymer; and
(b) a cationic agent associated with the negatively charged groups of particulate, which provides the particulate with a positive zeta-potential.

### Claim 2 (depends on 1)

The bioactive agent delivery composition of claim 1 wherein the first biocompatible polymer is a biodegradable polymer.

### Claim 3 (depends on 2)

The bioactive agent delivery composition of claim 2 wherein the first biocompatible polymer is an aliphatic polyester co-alkylene oxide block copolymer.

### Claim 4 (depends on 1)

The bioactive agent delivery composition of claim 1 wherein the first biocompatible polymer is present in the particulates in an amount in the range of 10% to 90% (wt).

### Claim 5 (depends on 1)

The bioactive agent delivery composition of claim 1 wherein the bioactive agent is present in the particulate in an amount in the range of 10% to 90% (wt).

### Claim 6 (depends on 1)

The bioactive agent delivery composition of claim 1 wherein the bioactive agent is a macrolide or a taxane.

### Claim 7 (depends on 1)

The bioactive agent delivery composition of claim 1 wherein the particulate further comprises an alkyl-substituted chromanol.

### Claim 8 (depends on 1)

The bioactive agent delivery composition of claim 1 wherein the particulate is spherical in shape.

### Claim 9 (depends on 1)

The bioactive agent delivery composition of claim 1 wherein the second biocompatible polymer is formed from a composition comprising an acid group-containing monomer.

### Claim 10 (depends on 9)

The bioactive agent delivery composition of claim 9 wherein the acid groups are partially neutralized.

### Claim 11 (depends on 1)

The bioactive agent delivery composition of claim 1 wherein the second biocompatible polymer is present in the particulate in an amount less than a combined amount of the first biocompatible polymer and bioactive agent.

### Claim 12 (depends on 1)

The bioactive agent delivery composition of claim 1 wherein the cationic agent is selected from the group consisting of cationic lipids, cationic polymers, and lipidoids.

### Claim 13 (depends on 1)

The bioactive agent delivery composition of claim 1, wherein the cationic agent is present in the composition in an amount in the range of 1% to 25% (wt).

### Claim 14 (depends on 1)

The bioactive agent delivery composition of claim 1 wherein the particulates have a size of less than 25 μm.

### Claim 15 (depends on 1)

A medical device having a surface associated with the bioactive agent delivery composition of claim 1.

### Claim 16 (depends on 15)

The medical device of claim 15, wherein the balloon is an angioplasty balloon.

### Claim 17 (depends on 15)

The medical device of claim 15 wherein the surface further comprises a hydrogel matrix and the composition is associated with the hydrogel matrix.

### Claim 18 (depends on 1)

A method for treating a subject comprising placing a bioactive agent delivery composition of claim 1 in a subject, wherein the bioactive agent released from the particulates treats a condition in the subject.

### Claim 19

A method for forming a bioactive agent delivery composition comprising a bioactive agent-containing particulate, comprising steps of:
forming a particle comprising a core particle comprising bioactive agent and a first biocompatible polymer, and a second biocompatible polymer comprising negatively charged groups, that is more water soluble first biocompatible polymer; and
contacting the particle with a composition comprising cationic agent.

### Claim 20 (depends on 19)

The method of claim 19 wherein the step of adding, the second biocompatible polymer comprises an acid group-containing biocompatible polymer, and the acid groups are partially or completely neutralized.
